01
What changed in pharmaceuticals regulation and policy this week?
Government decisions, new rules and policy shifts reported this week.
02
On September 9, 2026, the US FDA granted accelerated approval to AstraZeneca's drug Etcamah.
Read at citeline.com ↗03
The US Food and Drug Administration (FDA) announced that priority review voucher fees will decrease for the 2027 fiscal year.
Read at citeline.com ↗04
The National Commission into the Regulation of AI in Healthcare has published its recommendations for a future regulatory framework for AI in the UK healthcare sector.
Read at gov.uk ↗05
Jesse Mendelsohn, Senior Vice President at Model N, discusses the complexities of the 340B Drug Pricing Program in a Pharmaceutical Executive podcast episode.
Read at pharmexec.com ↗06
The US Food and Drug Administration (FDA) granted accelerated approval to AstraZeneca's drug camizestrant on September 8, 2026.
Read at fiercebiotech.com ↗07
Mexico has introduced a new regulatory reliance pathway for pharmaceutical products that have already been approved by Brazil's health authorities.
Read at citeline.com ↗08
The US Food and Drug Administration (FDA) is implementing stricter enforcement measures regarding clinical trial data originating from China and other foreign countries.
Read at citeline.com ↗8 of 10 regulation and policy events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What funding rounds and acquisitions happened in pharmaceuticals this week?
The week’s notable investments, financing rounds, acquisitions and strategic deals.
09
GE HealthCare is reportedly in advanced talks to acquire the radiopharmaceutical developer Sofie Biosciences.
Read at fiercebiotech.com ↗10
Private equity firm Warburg Pincus has acquired a stake in the Indian pharmaceutical company Koye Pharmaceuticals.
Read at citeline.com ↗11
In August 2026, Chinese advanced molecular therapy firms continued to secure significant investment funding.
Read at citeline.com ↗12
Kura Oncology has launched a new biotech spinout company to develop a next-generation diabetes therapy.
Read at fiercebiotech.com ↗13
Schrödinger has launched a new biotechnology company named Tectora Therapeutics, which will focus on immunology and inflammation research.
Read at fiercebiotech.com ↗14
Solstice Oncology has raised $225 million in a series A funding round.
Read at fiercebiotech.com ↗15
BrainChild Bio has raised $116 million in Series A financing to fund a pivotal Phase II trial for its lead CAR T-cell therapy candidate, BCB-276.
Read at genengnews.com ↗16
Health tech startup Forus has raised $150 million in a Series C funding round led by Bain Capital Ventures, bringing its total valuation to $3 billion.
Read at fiercehealthcare.com ↗8 of 13 funding and m&a events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What products launched in pharmaceuticals this week?
Notable product launches, releases and platform updates from the week.
17
Clinical research company nPhase launched an end-to-end clinical data management platform on September 10, 2026.
Read at fiercebiotech.com ↗18
H1 is utilizing connected intelligence to enhance clinical development processes.
Read at fiercebiotech.com ↗19
AstraZeneca's R&D chief Sharon Barr announced that the company has secured an FDA priority review for its IL-33 antibody treatment for chronic obstructive pulmonary disease (COPD).
Read at fiercebiotech.com ↗What financial results were reported in pharmaceuticals this week?
Earnings, guidance and other financial results reported this week.
20
Novartis shareholders are expressing concern over the company's M&A strategy following the failure of the muscle-wasting drug del-desiran in a late-stage trial.
Read at pharmexec.com ↗21
Novartis CEO Vas Narasimhan defended the company's recent mergers and acquisitions strategy on September 11, 2026.
Read at citeline.com ↗What court rulings and legal actions hit pharmaceuticals this week?
Court rulings, filings and legal actions reported this week.
22
A Fifth Circuit panel heard arguments on September 9, 2026, regarding Louisiana's attempt to block the FDA's 2023 decision to remove in-person dispensing requirements for mifepristone.
Read at courthousenews.com ↗What research was published in pharmaceuticals this week?
New research findings and studies published this week.
23
Moderna and Merck & Co. announced that their mRNA cancer vaccine successfully extended patient survival in a phase 3 clinical study.
Read at fiercebiotech.com ↗24
Researchers from the Wellcome Sanger Institute, University of Cambridge, and University College London published a study in Nature Genetics on September 11, 2026, regarding the impact of cancer treatments on healthy tissue.
Read at genengnews.com ↗25
Disc Medicine presented Phase II clinical trial data for its investigational agent DISC-3405.
Read at citeline.com ↗26
Researchers at the Salk Institute, led by Gerald Shadel, have identified a biological pathway where chronic exposure to interferon II (IFN-II) causes mitochondrial dysfunction, leading to immunosuppression in cancer.
Read at genengnews.com ↗27
Researchers at Cedars-Sinai Health Sciences University identified that the protein PD-L2 helps senescent cells evade the immune system, contributing to age-related dysfunction.
Read at genengnews.com ↗28
Novartis announced that its neuromuscular drug candidate delpacibart etedesiran failed the Phase III HARBOR trial for myotonic dystrophy type 1 (DM1) after missing the primary endpoint of vHOT improvement.
Read at genengnews.com ↗29
Biochemist Douglas Yao announced on September 8, 2026, that he synthesized a new schizophrenia drug candidate named PAC-3310 in his home garage.
Read at futurism.com ↗30
A recent study found that GLP-1 drug prescriptions for children aged 8 to 11 without diabetes increased between 2019 and 2026 in the United States.
Read at gizmodo.com ↗8 of 22 research events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What incidents and outages hit pharmaceuticals this week?
Incidents, outages and safety events reported this week.
31
The hacking group ShinyHunters leaked data belonging to 6.4 million individuals following a cyberattack on the medical supplier McKesson.
Read at theregister.com ↗32
Google's Mandiant threat intelligence team reported that extortion groups are increasingly targeting proprietary AI data, including models and research, for ransom.
Read at theregister.com ↗What partnerships were announced in pharmaceuticals this week?
Partnerships, integrations and joint projects announced this week.
33
Employers Health and Judi Health have partnered to launch StarkRx, a new cost-plus pharmacy benefit management (PBM) model.
Read at fiercehealthcare.com ↗34
ProBioGen and Transgene have expanded their existing collaboration through a new license agreement for the AGE1.CR.pIX cell line.
Read at genengnews.com ↗35
Carelon Research, led by President Mark Cziraky, has entered into a partnership with Manifold to enable researchers to analyze Carelon's real-world data alongside third-party datasets.
Read at pharmexec.com ↗36
Interra Health announced on September 10, 2026, that its health tech platform now supports the Medicare GLP-1 Bridge program.
Read at medcitynews.com ↗What people moved in and out of pharmaceuticals roles this week?
Executive appointments and departures reported this week.
37
In August 2026, the biopharmaceutical industry saw 12 companies announce workforce reductions affecting 526 employees, representing a 90% decrease compared to August 2025.
Read at biospace.com ↗38
On September 7, 2026, the U.S. Department of Health and Human Services (HHS) announced four permanent senior leadership appointments at the FDA.
Read at pharmexec.com ↗39
Law firm Fieldfisher has hired Franziska Katterbach as a partner to strengthen its life sciences practice in Germany.
Read at globallegalpost.com ↗3 of 5 people moves events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What else happened in pharmaceuticals this week?
Developments from the week that fit none of the other sections.
40
The Wall Street Journal published a market roundup on September 11, 2026, providing insights on healthcare companies including Novartis, Rohto Pharmaceutical, and IHH Healthcare.
Read at wsj.com ↗41
Nacho Quinones and Aisling O'Loughlin discuss the implementation of Synthetic Advisory Boards (S-ABs) in the biopharmaceutical industry as of September 2026.
Read at pharmexec.com ↗42
BioSpace reports that job postings for life sciences companies in California increased by 31% year-over-year in August 2026.
Read at biospace.com ↗43
The Wall Street Journal published a market analysis on September 10, 2026, covering major pharmaceutical companies including Novartis, Roche Holding, and GSK.
Read at wsj.com ↗44
Chantal Dresner reports on how life sciences companies are shifting their AI strategy from simple automation to holistic workforce planning.
Read at biospace.com ↗45
The Wall Street Journal published a market roundup on September 9, 2026, providing insights into the healthcare sector.
Read at wsj.com ↗6 of 8 other developments events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.